Zhejiang Jolly Pharmaceutical Co., Ltd. Class A

Zhejiang Jolly Pharmaceutical Co., Ltd. Class A

SSZSE:300181
12.85
CNY
+0.57
(+4.64%)
0.89EPS
14.92P/E
9.27BMarket Cap
Apr 22Next Earn
Zhejiang Jolly Pharmaceutical Co., Ltd. Class A
SZSE:300181
(Shenzhen Stock Exchange)

Recent

price

12.85

P/E

ratio

14.92

div

yld

5.86%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.65
0.54
0.64
0.79
0.95
1.19
1.4
1.23
1.2
1.5
1.79
2.36
2.98
2.79
3.71
4.43
4.7
Revenue per Share
0.1
0.1
0.11
0.15
0.19
0.15
0.12
0.07
0.03
0.04
0.15
0.29
0.45
0.55
0.73
0.92
0.89
Basic EPS, GAAP
0.06
-0.09
-0.01
0.01
-0.05
0.13
-0.14
-0.18
-0.12
0.15
0.36
0.17
0.23
0.23
0.05
0.18
- -
Free Cash Flow per Basic Share
0.02
0.02
0.09
0.04
0.15
0.17
0.11
0.04
0.05
0.11
0.05
0.11
0.24
0.31
0.46
0.62
0.75
Dividend per Share
0.51
1.27
1.31
1.43
1.49
2.12
2.17
2.23
2.2
2.15
2.63
3.03
3.85
3.89
3.95
4.53
4.53
Book Value per Share
0.43
1.21
1.23
1.36
1.23
1.78
1.78
1.85
1.83
1.82
2.3
2.71
3.58
3.6
3.63
4.19
3.63
Tangible Book Value per Share
405
515
539
530
543
565
600
645
609
608
609
619
607
696
696
687
696
Basic Weighted Avg Shares
263
279
344
419
515
671
840
794
730
911
1,091
1,457
1,805
1,942
2,578
3,041
3,271
Sales/Revenue/Turnover
15.35
15.92
15.93
16.8
20.32
13.23
7.95
8.45
6.94
8.13
12.53
16.34
19.26
22.54
24.12
26.21
23.91
Operating Margin (%)
10
11
14
19
22
30
37
39
42
48
54
57
61
65
72
81
- -
Depreciation Expense
41
51
62
81
103
85
72
45
21
26
89
179
273
383
508
632
617
Net Income, GAAP
8.5
10.09
10.44
10.37
11.4
11.2
13.81
13.42
17.7
18.07
12.71
13.64
11.91
12.51
13.53
14.98
14.69
Effective Tax Rate (%)
15.79
18.23
18.04
19.31
20.04
12.64
8.57
5.69
2.84
2.81
8.14
12.31
15.12
19.71
19.7
20.78
18.85
Profit Margin (%)
30
410
348
360
306
781
588
405
295
179
363
357
1,205
1,262
1,121
1,052
733
Working Capital
40
30
20
- -
42
68
121
110
104
88
57
24
32
17
49
29
64
LT Debt
207
684
706
773
872
1,436
1,472
1,490
1,435
1,408
1,719
1,983
2,760
2,774
2,819
3,241
3,235
Total Equity
10.75
7.5
6.28
7.39
9.21
5.17
2.81
2.4
1.36
1.31
4.93
8.96
11.43
13.03
16.56
17.71
15.69
Return on Invested Capital (%)
16.71
10.38
8.78
10.69
11.42
6.37
4.54
2.81
1.83
2.51
5.07
8.28
10.46
12.88
16.26
17.65
15.88
Return on Capital (%)
22.25
11.43
8.92
10.96
13.09
8.09
5.51
3.37
1.54
1.93
6.1
10.41
12.01
14.1
18.47
21.25
19.84
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
719
717
797
LT Borrowings
29
47
47
LT Finance Leases
18
18
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
701
701
701
Market Capitalization
10,963
9,890
9,265

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,598
2,523
2,339
Cash, Cash Equivalents & STI
718
648
340
Accounts Receivable, Net
982
981
1,060
Inventories
566
571
567
Total Current Liabilities
1,675
1,654
1,606
Payables & Accruals
- -
- -
- -
ST Debt
719
717
797
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.19%
14.32%
14.96%
Free Cash Flow
-10.39%
36.1%
264.94%
Net Income, GAAP
41.54%
50.3%
24.45%
Sales/Revenue/Turnover
17.19%
23.15%
17.96%
Total Cash Common Dividend
34.95%
72.69%
32.14%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
673
755
617
533
2,578
2025
824
775
- -
761
3,041
2026
898
866
746
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.22
0.18
0.13
0.73
2025
0.26
0.28
- -
0.18
0.92
2026
0.28
0.25
0.17
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.45
-0.01
0.02
0.46
2025
0.01
0.6
- -
0.01
0.62
2026
- -
0.36
0.38
- -
- -
Business
Zhejiang Jolly Pharmaceutical Co.,LTD is a national high-tech pharmaceutical enterprise engaged in the research, production, and marketing of traditional Chinese medicinal products and related pharmaceutical preparations. The company manufactures and sells core products including Wuling series products such as Wuling capsules and Wuling powder, Lingze tablets for benign prostatic hyperplasia, Linglianhua particles for menopausal syndrome treatment, Bailing tablets containing fermented cordyceps sinensis for respiratory and kidney-related conditions, and other traditional Chinese medicine tablets and granules. It also produces and markets a range of injections such as azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. The company incorporates modern bio-fermentation technology with traditional Chinese medicinal fungi, including the industrialized production of Wulingshen-based products and cordyceps fermentation powders. Founded in 2000 and headquartered in Huzhou, Zhejiang Province, China, Zhejiang Jolly Pharmaceutical operates with several subsidiaries such as Qinghai Everest Cordyceps Sinensis Pharmaceutical and Zhejiang Kaixin Medicine, and holds investments in medical services like those provided by Deqing No.3 People’s Hospital. It is listed on the Shenzhen Stock Exchange's Growth Enterprises Market under ticker 300181.SZ. In recent major developments, the company announced plans to raise up to 1.6 billion yuan via bond issuance to fund projects and strengthen capital resources, indicating a strategic expansion of its operational capabilities. In 2024, Zhejiang Jolly Pharmaceutical acquired a controlling stake in Lingyi (Hangzhou) Biotechnology, a gene therapy drug developer, enabling collaboration on the development and sales of neurological disease treatments including drugs for Parkinson's disease and Alzheimer's disease. Additionally, the company completed an acquisition of an 8% stake in Zhejiang Top Medicine Co., Ltd., signifying ongoing efforts to broaden its pharmaceutical portfolio and market reach. Zhejiang Jolly Pharmaceutical's business spans traditional Chinese medicine research and production, pharmaceutical biofermentation, and clinical medicine development and sales across China and internationally. The company emphasizes innovation in medicinal fungi pharmaceutical technology through its provincial high-tech research centers and national local co-operational engineering lab. Its targeted markets include hospitals, clinics, and pharmaceutical distribution networks focused on therapeutic areas such as respiratory health, neurological diseases, benign prostatic hyperplasia, and menopausal health. With a comprehensive production infrastructure covering raw materials, tablets, capsules, particles, and freeze-dried powder injections, Zhejiang Jolly Pharmaceutical maintains a significant presence in the Chinese pharmaceutical industry and is actively expanding its business scope through strategic investments and product development initiatives.